• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content

Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Like this document? Why not share!

Bio-Tech Report 210-U.S. Market for Diagnostic ....doc

on

  • 968 views

 

Statistics

Views

Total Views
968
Views on SlideShare
968
Embed Views
0

Actions

Likes
0
Downloads
7
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft Word

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Bio-Tech Report 210-U.S. Market for Diagnostic ....doc Bio-Tech Report 210-U.S. Market for Diagnostic ....doc Document Transcript

    • BI O -TECH SYSTEMS, INC. Market Research in the Health Care Field NEWS RELEASE 4167 W. Pinecrest Circle ───────────────── Las Vegas, Nevada 89121 April 1, 2005 ───────────────────────── (702) 456-7608 (702) 456-2189 FAX E-Mail: biotechsystems@earthlink.net Web Site: www.biotechsystems.com ─────────────────────────────────────────────────────────────────────────────── FOR IMMEDIATE RELEASE Contact: Marvin Burns Tel: (702) 456-7608 Fax: (702) 456-2189 BIO-TECH SYSTEMS ANNOUNCES A NEW RADIOPHARMACEUTICAL REPORT: Report 210: THE U.S MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS ────────────────────────────────────────────────────────────── PRESENT AND EMERGING RADIOPHARMACEUTICAL MARKETS, GOOD PROSPECTS FOR TARGETED ANTIBODIES AND PEPTIDES, CONTINUED HIGH GROWTH IN PET MARKET, POSITIVE IMPACE OF SPECT-CT ON NEW TARGETED AGENTS, MARKET ASSESSMENT AND SALES FORECASTS TO 2010 Bio-Tech Systems Inc. announces the publication of a comprehensive report with detailed analysis of the markets for diagnostic radiopharmaceuticals. This covers nuclear cardiology, neurology, functional nuclear medicine, targeted oncology and PET imaging. It includes emerging applications in imaging myocardial infarction, thrombus formations, in vivo infection imaging and new products for neurology and oncology. It also considers diagnostic applications in lymphoma colon cancer, lung cancer, bone cancer, endocrine cancer, brain cancer, liver cancer, pancreatic cancer and other cancers. Recent approval of two therapeutic radiopharmaceuticals has overlapped into the diagnostic market, creating a stronger link between targeted imaging and complementary therapeutic products. This has helped nuclear medicine, since nuclear imaging is required in all cases to assess biodistribution and dosing of therapeutic radiopharmaceuticals, as well as evaluate patient response to therapy. The report has a strong focus on new products and technology and emerging market opportunities. Many of the new diagnostic agents have a therapeutic counterpart, allowing nuclear imaging, with feedback with respect to targeting. In addition, new diagnostic products in cardiology, neurology and functional nuclear medicine are also covered in detail. This includes novel approaches to assessing myocardial viability, thrombus imaging, in vivo infection imaging and new products in neurology for diagnosing Parkinson’s disease and related neurological disorders. The prospects for growth of PET procedures are also covered, with analysis of expanding opportunities for FDG imaging as well as new specialized PET agents for oncology and neurology. The recent introduction of SPECT-CT imaging should revitalize conventional nuclear medicine by increasing the specificity of diagnosis, particularly with the newer targeted agents for oncology and neurology. This will bring nuclear medicine closer to the mainstream 1 ---more---
    • of radiology imaging, where the referral base is very large, as it has with PET-CT. This stimulus to nuclear medicine will encourage more investment from biopharmaceutical companies and venture groups that will ultimately promote future market growth. Diagnostic Radiopharmaceuticals: Market Analysis and Future Prospects U.S. sales of diagnostic radiopharmaceuticals reached $1.53 billion in 2004 and are expected to rise to $3.20 billion by 2010. Radiopharmaceutical sales grew 14.3% in 2004 and should continue growth in the range of 13%-16% through 2008. This growth will be based on introduction of new products, strong demand for cardiology procedures and increased sales of oncology products, particularly FDG for PET imaging. Sales of nuclear cardiology products will continue to drive the radiopharmaceutical market, with high utilization of nuclear perfusion studies coupled with advanced pharmacologic stress agents. Nuclear cardiology sales of $1.06 billion in 2004 will increase to $1.89 billion by 2010. FDG sales for oncology as well as cardiology and neurology will increase from $249 million in 2004 to $522 million by 2010. FDG distribution will continue to improve, allowing more widespread use of PET in community hospitals. With reimbursement stabilizing and procedure volume increasing, PET should become more profitable for providers as well as suppliers of FDG. In addition, new PET radiopharmaceuticals in the pipeline for specialized applications should add to these sales estimates. Market growth should also benefit from higher prices for many of the new products. More biopharmaceutical products for SPECT imaging will incorporate monoclonal antibody and peptide-based targeted agents, expanding the range of nuclear procedures. Availability of SPECT-CT will also add an important dimension to these new agents, aiding in image interpretation. This technical influx will help all segments of nuclear medicine, expanding the platform for molecular imaging. One effect is that clinicians will have more options as alternatives to higher risk and more costly invasive procedures. This will stimulate more research and investment, adding strength and stability to newer venture companies as well as those more established in the field. ABOUT THE AUTHOR Marvin Burns is president of Bio-Tech Systems, Inc., a firm that focuses on market research in the healthcare field. Burns specializes in market evaluation, where technological and scientific insight is important. The company has prepared numerous market research reports on diagnostic and therapeutic radiopharmaceuticals, brachytherapy, contrast media, interventional cardiology and medical imaging, which have been widely distributed. Burns has also served as a consultant to many international firms and venture groups in these fields. He has also been Technology Editor of Future Oncology, a publication widely circulated in the pharmaceutical and biotechnology industry reporting on new developments in cancer diagnosis and treatment. Burns is a graduate of MIT and Harvard Business School’s advanced management program. He has prepared over 100 publications and has 15 patents and invention disclosures. Prior to forming Bio-Tech Systems, he was employed by firms in life sciences, bioinstrumentation and medical imaging fields in general management, marketing and product development. He was also a hospital administrator in charge of professional and technical services including medical imaging, clinical laboratories, therapy services, and materials management. 2 ---more---
    • DIAGNOSTIC RADIOPHARMACEUTICALS: REPORT CONTENTS SECTION I: Market Status, Trends and Forecasts Analysis of recent sales, competitive challenges, new products in the pipeline and forces affecting future growth. Also provides sales forecasts to 2010. Products include: • Nuclear cardiology (heart perfusion agents, pharmacologic stressors, blood pool agents, myocardial viability agents, thrombus imaging and metabolic FDG imaging. • Functional nuclear medicine and cancer imaging products including NeutroSpec, ProstaScint, Octreoscan, Fibrimage, Infecton, and new PET imaging agents. • Neurology Imaging (New products for Parkinson’s and related syndromes, FDG imaging. SECTION II: Radiopharmaceutical Products and Technology • Technical principles and functional characteristics of radiopharmaceutical agents. • Radioisotope selection and optimization; production methods and trade-offs. • Analysis of emerging technologies and their probable impact on future markets. SECTION III: Clinical Applications • Discussion of clinical applications for radiopharmaceutical products and technologies. • Options in radiopharmaceutical selection and opportunities in PET imaging. • Analysis of product characteristics, performance benefits and trade-offs. SECTION IV: Current Developments and Emerging Technologies • Description of products in development within each major market segment including nuclear cardiology, neurology, targeted cancer imaging and infection imaging. • Interaction of diagnostic and therapeutic agents, selection of isotopes and new targeting methodologies. • Description of new technologies for diagnostic agents, such as receptor-specific proteins, antibodies and peptides, new cellular viability agents for cardiology, pretargeting in cancer imaging for increased dose delivery, and agents for imaging cellular necrosis. SECTION V: Industry Analysis • Analysis of current suppliers with individual product sales and market shares in 2004 • Market distribution, pricing strategies and new products in the pipeline. • Discussion of marketing goals, product plans, corporate partnerships and new ventures. SECTION VI: End-User Analysis • Analysis of end-user groups and comparative requirements for medical imaging. • Procedure mix and product utilization in hospitals and clinics. SECTION VII: Company Profiles • Background information on companies in the field and review of recent performance. • Discussion of each company's market activities and management strategies 3 ---more---
    • PARTIAL LIST OF EXHIBITS─DIAGNOSTIC RADIOPHARMACEUTICALS HISTORIC AND FORECAST SALES GROWTH HISTORIC AND FORECAST SALES OF OF DIAGNOSTIC RADIOPHARMACEUTICALS ISOTOPE PRODUCTS FOR FUNCTIONAL BY PRODUCT GROUP FROM 2000-2010 IMAGING, BY PRODUCT CATEGORY FROM 2000-2010 2004 DIAGNOSTIC RADIOPHARMA- CEUTICAL SALES SUMMARYBY HISTORIC AND FORECAST SALES OF FDG, PROCEDURE GROUP AND PRODUCT TYPE ANTIBODIES AND PEPTIDES FOR TARGETED CANCER IMAGING BY 2010 DIAGNOSTIC RADIOPHARMA- PRODUCT GROUP FROM 2000-2010 CEUTICAL SALES SUMMARY BY PROCEDURE GROUP AND PRODUCT TYPE 2004 SALES AND MARKET SHARES OF RADIOPHARMACY COMPANIES AND HISTORIC AND FORECAST SALES GROWTH INDEPENDENT NUCLEAR PHARMACIES OF NUCLEAR CARDIOLOGY AND VASCULAR IMAGING BY PRODUCT ANALYSIS OF RADIOPHARMACY CATEGORY FROM 2000-2010 REVENUES, COSTSAND GROSS PROFIT IN 2004 RELATIONSHIP OF NUCLEAR CARDIOLOGY PROCEDURES AND SALES TO GENERAL 2004 AVERAGE COST OF RADIOPHA- NUCLEAR MEDICINE FROM 2000-2010 RMACEUTICALS FOR RADIOPHARMACIES AND HOSPITAL END-USERS HISTORIC AND FORECAST SALES OF CARDIAC PERFUSION AGENTS BY DISTRIBUTION OF RADIOPHARMA- PRODUCT GROUP FROM 2000-2010 CEUTICAL SALES IN THE U.S. IN 2004, MANUFACTURER'S SALES VOLUME BY HISTORIC AND FORECAST SALES OF PRODUCT CATEGORY PHARMACOLOGIC STRESSORS FOR CARDIAC IMAGING BY PRODUCT 2004 SALES OF THALLIUM FOR HEART CATEGORY FROM 2000-2010 PERFUSION STUDIES, RADIOPHA- RMACEUTICAL SUPPLIER AND MARKET SALES OF CARDIOLOGY AGENTS FOR SHARE MYOCARDIAL VIABILITY, THROMBUS AND VASCULAR IMAGING BY PRODUCT GROUP 2004 SALES OF CARDIOLITE FOR HEART FROM 2000-2010 PERFUSION STUDIES, RADIOPHARMA- CEUTICAL SUPPLIER AND MARKET SHARE SALES OF GENERAL NUCLEAR MEDICINE PRODUCTS FOR FUNCTIONAL STUDIES 2004 SALES OF MYOVIEW FOR HEART AND TARGETED CANCER IMAGING FROM PERFUSION STUDIES, RADIOPHARMA- 2000-2010 CEUTICAL SUPPLIER AND MARKET SHARE HISTORIC AND FORECAST GROWTH OF 2004 SALES OF CARDIOGEN, RUBIDIUM-81 TECHNETIUM-BASED PROCEDURES FROM GENERATOR, FOR HEART PERFUSION 2000-2010 STUDIES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE HISTORIC AND FORECAST SALES OF TECHNETIUM AND TECHNETIUM-BASED 2004 SALES OF ADENOSCAN FOR PRODUCTS FROM 2000-2010 PHARMACOLOGIC STRESS, RADIO- PHARMACEUTICAL SUPPLIER AND HISTORIC AND FORECAST SALES OF MARKET SHARE TECHNETIUM AND TECHNETIUM KITS FOR GENERAL PURPOSE IMAGING BY PRODUCT 2004 SALES OF PYP-PYROPHOSPHATE KITS CATEGORY FROM 2000-2010 FOR HEART IMAGING, RADIOPHARM- ACEUTICAL SUPPLIER AND MARKET YEAR 2004 RADIOPHARMACEUTICAL SHARE SALES SUMMARY, MANUFACTURERS' SALES DOLLAR VOLUME AND MARKET SHARE 4 ---more---
    • PARTIAL LIST OF EXHIBITS─DIAGNOSTIC RADIOPHARMACEUTICALS CLINICAL INDICATIONS FOR NUCLEAR RADIOPHARMACEUTICAL SUPPLIER AND IMAGING PROCEDURES MARKET SHARE 2004 SALES OF TECHNETIUM GENERATORS, 2004 SALES OF XENON FOR LUNG RADIOPHARMACEUTICAL SUPPLIER AND VENTILATION STUDIES, RADIOPHARMA- MARKET SHARE CEUTICAL SUPPLIER AND MARKET SHARE 2004 SALES OF TECHNETIUM DTPA KITS 2004 SALES OF INDIUM OXINE FOR IMAGING FOR AEROSOL LUNG VENTILATION, BRAIN INFLAMMATORY PROCESSES, AND KIDNEY SCANS, RADIOPHARMA- RADIOPHARMACEUTICAL SUPPLIER AND CEUTICAL SUPPLIER AND MARKET SHARE MARKET SHARE 2004 SALES OF TECHNETIUM SULFUR 2004 SALES OF NEUTROSPEC FOR IN VIVO COLLOID KITS FOR LIVER SCANS, IMAGING OF INFLAMMATORY PROCESSES, RADIOPHARMACEUTICAL SUPPLIER AND RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE MARKET SHARE 2004 SALES OF MDP AND HDP KITS FOR 2004 SALES OF PROSTASCINT FOR IMAGING BONE IMAGING, RADIOPHARMACEUTICAL PROSTATE CANCER, RADIOPHARMA- SUPPLIER AND MARKET SHARE CEUTICAL SUPPLIER AND MARKET SHARE 2004 SALES OF MACRO-AGGREGATED 2004 SALES OF CEA SCAN FOR IMAGING ALBUMIN FOR LUNG PERFUSION SCANS, COLORECTAL CANCER, SUPPLIER AND RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE MARKET SHARE 2004 SALES OF OCTREOSCAN FOR IMAGING 2004 SALES OF TECHNETIUM BILIARY NEUROENDOCRINE TUMORS, SUPPLIER AGENTS FOR GALL BLADDER STUDIES, AND MARKET SHARE RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 2004 SALES OF INDIUM CHLORIDE FOR COMPOUNDING WITH CANCER IMAGING 2004 SALES OF TECHNESCAN MAG-3 FOR AGENTS, SUPPLIER AND MARKET SHARE KIDNEY FUNCTION STUDIES, RADIOPHARMACEUTICAL SUPPLIER AND 2004 SALES OF FDG FOR METABOLIC MARKET SHARE IMAGING IN ONCOLOGY, NEUROLOGY AND CARDIOLOGY, RADIOPHARMACEUTICAL 2004 SALES OF IODINE 131 FOR THYROID SUPPLIER AND MARKET SHARE IMAGING AND KIDNEY SCANS, RADIOPHARMACEUTICAL SUPPLIER AND DISTRIBUTION OF HOSPITAL DIAGNOSTIC MARKET SHARE IMAGING PROCEDURES IN THE U.S. BY HOSPITAL BED SIZE IN 2004 2004 SALES OF IODINE 123 FOR THYROID SCANS, RADIOPHARMACEUTICAL RELATIVE PROCEDURE VOLUME AMONG SUPPLIER, SALES DOLLAR VOLUME AND DIFFERENT IMAGING MODALITIES, MARKET SHARE PERCENTAGE RELATIONSHIP BY HOSPITAL BED SIZE IN 2004 2004 SALES OF CERETEC FOR BRAIN PERFUSION STUDIES AND WHITE BLOOD RELATIVE ACTIVITY INDEX AMONG CELL LABELING, RADIOPHARMACEUTICAL DIFFERENT IMAGING MODALITIES SUPPLIER AND MARKET SHARE PROCEDURES PER BED PER YEAR BY HOSPITAL BED SIZE IN 2004 2004 SALES OF NEUROLITE FOR BRAIN PERFUSION STUDIES, RADIOPHARMA- CEUTICAL SUPPLIER AND MARKET SHARE 2004 SALES OF GALLIUM FOR SCANS OF TUMORS, ABSCESSES AND INFLAMMATION,
    • COMPANY PROFILES INCLUDE AMERSHAM DIVISION. OF GE DOW CHEMICAL CO. ANTISOMA LTD. (UK) DRAXIMAGE, INC.) BERLEX LABORATORIES EASTERN ISOTOPES CIS BIOINTERNATIONAL FUJISAWA USA INC. (BERLEX) IMMUNOMEDICS, INC. BEST MEDICAL INTERNATIONAL LYNNTECH INC. BRISTOL MYERS SQUIBB MEDICAL IMAGING MALLINCKRODT INC. (TYCO) BIOGEN-IDEC MDS NORDION PHARMACEUTICALS MOLECULAR INSIGHT BOSTON LIFE SCIENCES INC. PHARMACEUTICALS NEORX CORPORATION BRACCO DIAGNOSTICS PALATIN TECHNOLOGIES INC. CARDINAL HEALTH. PEREGRINE PHARMACEUTICALS COPHAROS, INC. PETNet PHARMACEUTICALS CORIXA CORPORATION VITA MEDICAL (AUSTRALIAN) CYTOGEN CORPORATION 6
    • ORDER FORM Report No. 210 – US MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS The report is priced at $7,500 including postage. Electronic PDF copies are available. Please make check payable to: BIO-TECH SYSTEMS, INC. For wire transfer, make deposit to: BANK OF AMERICA, NEVADA Post Office Box 98600 Las Vegas, Nevada 89193-8600 Routing/ABA #122 400 724 For credit to: BIO-TECH SYSTEMS, INC. Account No. 270 113 178 Mailing Information Name:______________________________Title:_____________________________________ Company:____________________________________________________________________ Address______________________________________________________________________ City:_______________________State________Zip Code__________Country_____________ Telephone_______________________________FAX_________________________________ E-Mail_______________________________________________ P.O. #:______________________________Signature_________________________________ Credit Cards: VISA, MC, AMEX, DISCOVER (Check One) Credit Card No._______________________________________________________________ Expiration: Month_______Year_____Name on Card :_________________________________ Signature____________________________________________________________________ Address for Credit Card Statements________________________________________________ ____________________________________________________________________________ Return to: BIO-TECH SYSTEMS, INC. 4167 W. Pinecrest Circle Las Vegas, Nevada 89121 Telephone: (702) 456-7608 FAX (702) 456-2189 E-Mail: biotechsystems@earthlink.net